Merck KGaA Darmstadt Germany has announced its largest investment in Asia through a groundbreaking ceremony of its state-of-the-art € 300 million Bioprocessing Production Center in Daejeon, South Korea.

The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies.

Once completed, the investment will create as many as 300 new jobs and continue to grow and support global demand for critical drugs and therapies.

The ceremony witnessed the presence of the leadership team of Merck including Matthias Heinzel, CEO of the Life Science business at Merck; Karen Madden, Chief Technology Officer, Life Science business of Merck; Sebastián Arana, Head, Process Solutions, Life Science business of Merck; Ivan Donzelot, Head of Integrated Supply Chain Operations at Merck joined by Cheong Inkyo, Trade Minister of Korea, Lee Jang Woo,  Mayor of Daejeon, Ambassador Georg Schmidt along with other dignitaries and partners.